BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer
| Autor: | Simon Thezenas, Frédéric Bibeau, Pierre-Jean Lamy, William Jacot, Anne-Claire Laberenne, Jean-Pierre Bleuse, Gilles Romieu, Evelyne Lopez-Crapez, Cathy Viglianti, Romain Senal |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Cancer Research DNA Repair DNA repair BRCA Poly (ADP-Ribose) Polymerase-1 Breast Neoplasms Triple Negative Breast Neoplasms PARP-1 Biology Methylation Breast cancer Surgical oncology Risk Factors medicine Genetics Biomarkers Tumor Humans skin and connective tissue diseases Promoter Regions Genetic Lymph node Aged Neoplasm Staging Retrospective Studies Regulation of gene expression BRCA1 Protein Intracellular Signaling Peptides and Proteins DNA Methylation Middle Aged medicine.disease Prognosis 53BP1 Enzyme Activation Gene Expression Regulation Neoplastic medicine.anatomical_structure Oncology Hormone receptor DNA methylation Cancer research Female Neoplasm Grading Poly(ADP-ribose) Polymerases Tumor Suppressor p53-Binding Protein 1 Signal Transduction Research Article |
| Zdroj: | BMC Cancer |
| ISSN: | 1471-2407 |
| Popis: | Background: Poly(adenosine diphosphate–ribose) polymerase 1 (PARP-1) and the balance between BRCA1 and 53BP1 play a key role in the DNA repair and cell stress response. PARP inhibitors show promising clinical activity in metastatic triple negative (TN) or BRCA-mutated breast cancer. However, a comprehensive analysis of PARP-1 activity, BRCA1 promoter methylation and 53BP1 expression in tumours without known BRCA1 mutation has not yet been carried out. Methods: We investigated cytosolic PARP-1 activity, 53BP1 protein levels and BRCA1 promoter methylation in 155 surgical breast tumour samples from patients without familial breast cancer history or known BRCA1 mutations who were treated between January 2006 and November 2009 and evaluated their statistical association with classical predictive and prognostic factors. Results: The mitotic count score was the only parameter clearly associated with PARP-1 activity. BRCA1 promoter hypermethylation (15.4% of all cancers) was significantly associated with uPA and PAI-1 levels, tumour grade, mitotic count score, hormone receptor and HER2 negative status and TN profile (29% of TN tumours showed BRCA1 promoter hypermethylation compared to 5% of grade II-III hormone receptor-positive/HER2-negative and 2% of HER2-positive tumours). No statistical association was found between BRCA1 promoter hypermethylation and PARP-1 activity. High 53BP1 protein levels correlated with lymph node positivity, hormone receptor positivity, molecular grouping, unmethylated BRCA1 promoter and PARP-1 activity. In TN tumours, BRCA1 promoter methylation was only marginally associated with age, PARP-1 activity was not associated with any of the tested clinico-pathological factors and high 53BP1 protein levels were significantly associated with lymph node positivity. Only 3 of the 14 TN tumours with BRCA1 promoter hypermethylation presented high 53BP1 protein levels. Conclusions: Breast cancers that harbour simultaneously high 53BP1 protein level and BRCA1 promoter hypermethylation and are the putative target population of drugs targeting DNA repair appear to be restricted to a small subgroup of TN tumours. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink